Abstract 1243P
Background
Ocular surface squamous neoplasia (OSSN) is a common eye surface neoplastic disease ranging from non-invasive conjunctival intraepithelial neoplasia (CIN) to invasive forms of squamous cell carcinoma (SCC) that accounts for approximately 10% of ocular surface lesions. Early detection of OSSN is crucial for effective treatment. However, clinical symptoms of OSSN vary, which can result in delayed or inappropriate diagnosis without appropriate diagnostic methods. Currently, the diagnosis of OSSN relies on clinical suspicion confirmed by impression cytology or biopsy, which are invasive and may not detect small lesions. This study aims to introduce an artificial intelligence data analysis framework to empower a newly designed autofluorescence hyperspectral imaging technology developed in our group for OSSN detection.
Methods
We recruited 20 patients who had previously been diagnosed with OSSN. Biopsy specimens were collected from the patients and reprocessed without staining to obtain autofluorescence microscopy images using 25 spectral channels, each with a distinctive excitation-emission wavelength. The spectral images were pre-processed to remove unwanted random noise and then spectral features were extracted from the epithelial section of tissue images. Further, the spectral features were used to form an artificial feature image patch to train a convolutional neural network for image classification.
Results
The technique was evaluated against pathological assessment, and results showed the multispectral analysis was able to detect OSSN in all tested patients (P-value < 0.05). The trained classifier on OSSN and normal sections was found to have great performance (AUC > 83%). The maps produced by the analysis were in close agreement with margins observed in H&E sections. The fully automated diagnostic method based on AI methodology produced maps of the neoplastic-non neoplastic interface that could be generated in quasi-real time and used for intraoperative assessment.
Conclusions
The study demonstrated the feasibility of using AI empowered hyperspectral autofluorescence imaging to detect OSSN and the potential for the technique to be used as a diagnostic tool in future clinical applications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cancer Institute NSW.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1785P - Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide plus/minus zoledronic acid: The BonEnza study
Presenter: Alberto Dalla Volta
Session: Poster session 14
1787P - Prostate specific membrane antigen positron emission tomography (PSMA PET)-directed clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC): Implications for the STAMPEDE2 trial design
Presenter: Hoda Abdel-Aty
Session: Poster session 14
1789P - Low- and high-volume disease in mHSPC: From CHAARTED to PSMA PET
Presenter: Lena Unterrainer
Session: Poster session 14
1790P - Utilisation rates of treatment intensification for metastatic hormone sensitive prostate cancer (mHSPC) in England, UK
Presenter: Joanna Dodkins
Session: Poster session 14
1791P - Molecular profiling and prognostic relevance of low PTEN expression in metastatic hormone-sensitive prostate cancer patients
Presenter: Marta Garcia De Herreros
Session: Poster session 14
1792P - Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 14
1793P - PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
Presenter: Jose Arranz Arija
Session: Poster session 14